Phaseline

Targets › CPA2

CPA2 (Carboxypeptidase A2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Jul 2030.

Carboxypeptidase that catalyzes the release of a C-terminal amino acid, with a preference for large aromatic C-terminal residues. (UniProt, P48052)

Open in Phaseline: the race on CPA2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Northwell HealthPost transplant cyclophosphamide
Alkylating agent; prodrug requiring hepatic metabolism to active phosphoramide mustard tha
CPA1, CPA2Phase 1GVHD - Graft-Versus-Host DiseaseJul 2030

Conditions

GVHD - Graft-Versus-Host Disease (1)

Modalities

small molecule (1)

Companies

Northwell Health (1)

Related targets

CPA1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.